...
首页> 外文期刊>Langmuir: The ACS Journal of Surfaces and Colloids >Pluronics F-127/L-81 Binary Hydrogels as Drug-Delivery Systems: Influence of Physicochemical Aspects on Release Kinetics and Cytotoxicity
【24h】

Pluronics F-127/L-81 Binary Hydrogels as Drug-Delivery Systems: Influence of Physicochemical Aspects on Release Kinetics and Cytotoxicity

机译:Pluronics F-127 / L-81二元水凝胶作为药物递送系统:理化方面对释放动力学和细胞毒性的影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

We investigated the structure of the binary mixture of Pluronic F-127 (PL F-127) and Pluronic L-81 (PL L-81), as hydrogels for sumatriptan delivery and investigated the mixture possible use via subcutaneous route for future applications as a long-acting antimigraine formulation. We studied the drug micelle interaction by dynamic light scattering and differential scanning calorimetry, sol gel process by rheology, and small-angle X-ray scattering (SAXS). We also employed pharmaceutical formulation aspects by dissolution rate, release profile, and cytotoxicity studies for apoptosis and/or necrosis in fibroblasts (3T3) and neural cells (Neuro 2a). Mice liar hydrodynamic diameter studies revealed the formation of binary PL-micelles by association of PL F-127/PL L-81. The mixed micelle and binary hydrogels formation was also verified by only one phase transition temperature for all formulations, even in the presence of sumatriptan. The characterization of the hydrogel supramolecular organization by SAXS, rheology studies, and in vitro dissolution/release results showed a probable relationship between the transition of the lamellar to the hexagonal phase and the lower release constant values observed, indicating that PL L-81 participates in micelle-hydrogel formation and aggregation processes. Furthermore, the reduced cytotoxicity (annexin V-fluorescein isothiocyanate positive staining), with minor PL L-81 concentration, points to its potential use for the development of binary PL-systems containing sumatriptan capable of modulating the gelation process. This use may employ the minimum PL concentration and be interesting for pharmaceutical applications, particularly for migraine treatment.
机译:我们研究了Pluronic F-127(PL F-127)和Pluronic L-81(PL L-81)的二元混合物的结构,作为舒马普坦递送的水凝胶,并研究了该混合物可能通过皮下途径用于未来的应用。长效抗偏头痛制剂。我们通过动态光散射和差示扫描量热法,流变学的溶胶凝胶法和小角X射线散射(SAXS)研究了药物胶束相互作用。我们还通过溶出度,释放曲线和细胞毒性研究对成纤维细胞(3T3)和神经细胞(Neuro 2a)的凋亡和/或坏死进行了药物制剂方面的研究。小鼠骗子流体动力学直径研究揭示了通过PL F-127 / PL L-81的结合形成二元PL胶束。对于所有制剂,即使存在舒马曲坦,也仅通过一个相变温度来验证混合胶束和二元水凝胶的形成。 SAXS对水凝胶超分子组织的表征,流变学研究和体外溶出/释放结果表明,层状分子向六方相的转变与观察到的较低释放常数之间可能存在关系,表明PL L-81参与了胶束-水凝胶的形成和聚集过程。此外,较低的PL L-81浓度降低了的细胞毒性(annexin V-荧光素异硫氰酸酯阳性染色)表明,其潜在用途可用于开发能够调节凝胶化过程的舒马普坦二元PL系统。这种用途可以采用最小的PL浓度,并且对于药物应用,尤其是对偏头痛的治疗而言是令人感兴趣的。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号